炎症性肠病的当前阶段：接下来会怎样？
Current stage in inflammatory bowel disease: What is next?
作者信息
Gómez-Gómez Gonzalo Jesús, Masedo Ángeles, Yela Carmen, Martínez-Montiel Maria del Pilar, Casís Begoña
机构信息
Gonzalo Jesús Gómez-Gómez, Ángeles Masedo, Carmen Yela, Maria del Pilar Martínez-Montiel, Begoña Casís, Unidad de Enfermedad Inflamatoria Intestinal, Hospital 12 de Octubre, 28045 Madrid, Spain.
出版信息
World J Gastroenterol. 2015 Oct 28;21(40):11282-303. doi: 10.3748/wjg.v21.i40.11282.
Abstract
In recent years, the incidence of inflammatory bowel disease (IBD) has been on the rise, extending to countries where it was infrequent in the past. As a result, the gap between high and low incidence countries is decreasing. The disease, therefore, has an important economic impact on the healthcare system. Advances in recent years in pharmacogenetics and clinical pharmacology have allowed for the development of treatment strategies adjusted to the patient profile. Concurrently, new drugs aimed at inflammatory targets have been developed that may expand future treatment options. This review examines advances in the optimization of existing drug treatments and the development of novel treatment options for IBD.
摘要
近年来，炎症性肠病（IBD）的发病率一直在上升，范围已扩大到过去发病率较低的国家。因此，高发病率国家和低发病率国家之间的差距正在缩小。该疾病对医疗保健系统具有重要的经济影响。近年来，药物遗传学和临床药理学的进展使得能够制定根据患者情况调整的治疗策略。同时，针对炎症靶点的新药已被开发出来，这可能会扩大未来的治疗选择。本综述探讨了现有药物治疗优化方面的进展以及IBD新治疗选择的开发情况。
相似文献
1
Current stage in inflammatory bowel disease: What is next?炎症性肠病的当前阶段：接下来会怎样？
World J Gastroenterol. 2015 Oct 28;21(40):11282-303. doi: 10.3748/wjg.v21.i40.11282.
2
Why innovation in inflammatory bowel disease drug development will impact your practice.为何炎症性肠病药物研发创新会对你的医疗实践产生影响。
Clin Gastroenterol Hepatol. 2011 Mar;9(3):211-3. doi: 10.1016/j.cgh.2010.12.007.
3
Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease.炎症性肠病治疗策略的发病机制及反应预测因素的最新进展
World J Gastroenterol. 2015 Nov 28;21(44):12519-43. doi: 10.3748/wjg.v21.i44.12519.
4
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.综述文章：用于治疗炎症性肠病的药物的药代动力学和药效学
Eur J Clin Pharmacol. 2015 Jul;71(7):773-99. doi: 10.1007/s00228-015-1862-7. Epub 2015 May 27.
5
Advances in the management of inflammatory bowel disease.炎症性肠病的治疗进展。
Intern Med J. 2010 Apr;40(4):258-64. doi: 10.1111/j.1445-5994.2010.02163.x. Epub 2010 Jan 4.
6
Advances in inflammatory bowel diseases in children.儿童炎症性肠病的进展
Minerva Pediatr. 2012 Jun;64(3):257-70.
7
Cardiovascular involvement in inflammatory bowel disease: Dangerous liaisons.炎症性肠病中的心血管受累：危险关联。
World J Gastroenterol. 2015 Sep 7;21(33):9688-92. doi: 10.3748/wjg.v21.i33.9688.
8
On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.炎症性肠病中硫嘌呤类药物的治疗药物监测：药理学、药物基因组学、药物不耐受及临床相关性。
Curr Drug Metab. 2009 Nov;10(9):981-97. doi: 10.2174/138920009790711887.
9
Conventional drug therapy for inflammatory bowel disease.炎症性肠病的传统药物治疗
Scand J Gastroenterol. 2015 Jan;50(1):90-112. doi: 10.3109/00365521.2014.968864.
10
[Drug delivery strategies for targeted treatment of inflammatory bowel disease].[用于炎症性肠病靶向治疗的药物递送策略]
Z Gastroenterol. 2015 Mar;53(3):226-34. doi: 10.1055/s-0034-1398793. Epub 2015 Feb 27.
引用本文的文献
1
A hepatocyte-specific transcriptional program driven by Rela and Stat3 exacerbates experimental colitis in mice by modulating bile synthesis.由 Rela 和 Stat3 驱动的肝细胞特异性转录程序通过调节胆汁合成加剧了小鼠实验性结肠炎。
Elife. 2024 Aug 13;12:RP93273. doi: 10.7554/eLife.93273.
2
Nano-based Therapeutics for Rheumatoid Arthritis: Recent Patents and Development.用于类风湿性关节炎的纳米疗法：近期专利与进展
Recent Pat Nanotechnol. 2025;19(1):56-75. doi: 10.2174/1872210518666230905155459.
3
Mesenchymal (Stem) Stromal Cells Based as New Therapeutic Alternative in Inflammatory Bowel Disease: Basic Mechanisms, Experimental and Clinical Evidence, and Challenges.基于间充质（干）基质细胞的新型治疗选择在炎症性肠病中的应用：基础机制、实验和临床证据及挑战。
Int J Mol Sci. 2022 Aug 10;23(16):8905. doi: 10.3390/ijms23168905.
4
Pretreatment with licochalcone a enhances therapeutic activity of rat bone marrow mesenchymal stem cells in animal models of colitis.用甘草查耳酮A预处理可增强大鼠骨髓间充质干细胞在结肠炎动物模型中的治疗活性。
Iran J Basic Med Sci. 2021 Aug;24(8):1050-1057. doi: 10.22038/ijbms.2021.56520.12616.
5
Tailored Hydrogels as Delivery Platforms for Conditioned Medium from Mesenchymal Stem Cells in a Model of Acute Colitis in Mice.定制水凝胶作为小鼠急性结肠炎模型中间充质干细胞条件培养基的递送平台
Pharmaceutics. 2021 Jul 23;13(8):1127. doi: 10.3390/pharmaceutics13081127.
6
Serum cytokine, chemokine, and growth factor profiles and their modulation in inflammatory bowel disease.血清细胞因子、趋化因子和生长因子谱及其在炎症性肠病中的调节
Medicine (Baltimore). 2019 Sep;98(38):e17208. doi: 10.1097/MD.0000000000017208.
7
Rheumatoid Arthritis: A Brief Overview of the Treatment.类风湿关节炎：治疗简述。
Med Princ Pract. 2018;27(6):501-507. doi: 10.1159/000493390. Epub 2018 Sep 2.
8
Flavonoids from Engineered Tomatoes Inhibit Gut Barrier Pro-inflammatory Cytokines and Chemokines, SAPK/JNK and p38 MAPK Pathways.工程番茄中的类黄酮可抑制肠道屏障促炎细胞因子和趋化因子、SAPK/JNK和p38丝裂原活化蛋白激酶信号通路。
Front Nutr. 2017 Dec 18;4:61. doi: 10.3389/fnut.2017.00061. eCollection 2017.
9
Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis.扁桃体来源的间充质干细胞在葡聚糖硫酸钠诱导的实验性小鼠结肠炎中的治疗潜力
PLoS One. 2017 Aug 30;12(8):e0183141. doi: 10.1371/journal.pone.0183141. eCollection 2017.
10
Anti-inflammatory effect of cannabinoid agonist WIN55, 212 on mouse experimental colitis is related to inhibition of p38MAPK.大麻素激动剂WIN55,212对小鼠实验性结肠炎的抗炎作用与抑制p38丝裂原活化蛋白激酶有关。
World J Gastroenterol. 2016 Nov 21;22(43):9515-9524. doi: 10.3748/wjg.v22.i43.9515.
本文引用的文献
1
Natalizumab induction and maintenance therapy for Crohn's disease.那他珠单抗用于克罗恩病的诱导和维持治疗。
N Engl J Med. 2015 May 21;372(21):2074. doi: 10.1056/NEJMx140055.
2
Briakinumab for treatment of Crohn's disease: results of a randomized trial.布罗达单抗治疗克罗恩病：一项随机试验的结果
Inflamm Bowel Dis. 2015 Jun;21(6):1329-40. doi: 10.1097/MIB.0000000000000366.
3
Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review.粪菌移植作为胃肠病学的新型疗法：一项系统综述。
World J Gastroenterol. 2015 May 7;21(17):5359-71. doi: 10.3748/wjg.v21.i17.5359.
4
Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?干细胞治疗炎症性肠病：一种有前途的治疗策略？
World J Stem Cells. 2015 Mar 26;7(2):343-51. doi: 10.4252/wjsc.v7.i2.343.
5
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.蒙歌根，一种口服 SMAD7 反义寡核苷酸，与克罗恩病。
N Engl J Med. 2015 Mar 19;372(12):1104-13. doi: 10.1056/NEJMoa1407250.
6
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.托法替布治疗活动性溃疡性结肠炎的随机试验：基于患者报告结局的疗效分析。
BMC Gastroenterol. 2015 Feb 5;15:14. doi: 10.1186/s12876-015-0239-9.
7
[Non-invasive follow up of patients with inflammatory bowel diseases].[炎症性肠病患者的非侵入性随访]
Rev Prat. 2014 Nov;64(9):1256-61.
8
Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.教学医院环境下炎症性肠病患者英夫利昔单抗的治疗药物监测：一项前瞻性队列研究的结果
Eur J Gastroenterol Hepatol. 2015 Mar;27(3):242-8. doi: 10.1097/MEG.0000000000000279.
9
Optimizing the use of biological therapy in patients with inflammatory bowel disease.优化炎症性肠病患者的生物治疗。
Gastroenterol Rep (Oxf). 2015 Feb;3(1):63-8. doi: 10.1093/gastro/gou087. Epub 2015 Jan 6.
10
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.安罗替尼，一种抗白细胞介素 13 单克隆抗体，在活动期 UC 中的疗效和安全性：来自 IIa 期随机多中心研究的结果。
Gut. 2015 Jun;64(6):894-900. doi: 10.1136/gutjnl-2014-308337. Epub 2015 Jan 7.
Zotero 插件